Most cited article(s)

You have access
Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.
W Tassaneeyakul, D J Birkett, M E Veronese, M E McManus, R H Tukey, L C Quattrochi, H V Gelboin and J O Miners

Journal of Pharmacology and Experimental Therapeutics April 1993, 265 (1) 401-407;
You have access
Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery
Joseph W. Polli, Stephen A. Wring, Joan E. Humphreys, Liyue Huang, Jonathon B. Morgan, Lindsey O. Webster and Cosette S. Serabjit-Singh

Journal of Pharmacology and Experimental Therapeutics November 2001, 299 (2) 620-628;
You have access
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Bernie Scallon, Ann Cai, Nancy Solowski, Amy Rosenberg, Xiao-Yu Song, David Shealy and Carrie Wagner

Journal of Pharmacology and Experimental Therapeutics May 2002, 301 (2) 418-426; DOI: https://doi.org/10.1124/jpet.301.2.418
You have access
Antagonist binding profiles of five cloned human muscarinic receptor subtypes.
F Dörje, J Wess, G Lambrecht, R Tacke, E Mutschler and M R Brann

Journal of Pharmacology and Experimental Therapeutics February 1991, 256 (2) 727-733;
You have access
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Murielle Rinaldi-Carmona, Francis Barth, José Millan, Jean-Marie Derocq, Pierre Casellas, Christian Congy, Didier Oustric, Martine Sarran, Monsif Bouaboula, Bernard Calandra, Marielle Portier, David Shire, Jean-Claude Brelière and Gérard Le Fur

Journal of Pharmacology and Experimental Therapeutics February 1998, 284 (2) 644-650;
You have access
Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs.
O Laneuville, D K Breuer, D L Dewitt, T Hla, C D Funk and W L Smith

Journal of Pharmacology and Experimental Therapeutics November 1994, 271 (2) 927-934;
You have access
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Matthew J. Fell, Christian Mirescu, Kallol Basu, Boonlert Cheewatrakoolpong, Duane E. DeMong, J. Michael Ellis, Lynn A. Hyde, Yinghui Lin, Carrie G. Markgraf, Hong Mei, Michael Miller, Frederique M. Poulet, Jack D. Scott, Michelle D. Smith, Zhizhang Yin, Xiaoping Zhou, Eric M. Parker, Matthew E. Kennedy and John A. Morrow

Journal of Pharmacology and Experimental Therapeutics December 2015, 355 (3) 397-409; DOI: https://doi.org/10.1124/jpet.115.227587
You have access
Pharmacological Characterization of Recombinant Human Neuronal Nicotinic Acetylcholine Receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 Expressed in Xenopus Oocytes
Laura E. Chavez-Noriega, James H. Crona, Mark S. Washburn, Arturo Urrutia, Kathryn J. Elliott and Edwin C. Johnson

Journal of Pharmacology and Experimental Therapeutics January 1997, 280 (1) 346-356;
You have access
Drug Synergism: Its Detection and Applications
Ronald J. Tallarida

Journal of Pharmacology and Experimental Therapeutics September 2001, 298 (3) 865-872;
You have access
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.
P Patrignani, M R Panara, A Greco, O Fusco, C Natoli, S Iacobelli, F Cipollone, A Ganci, C Créminon and J Maclouf

Journal of Pharmacology and Experimental Therapeutics December 1994, 271 (3) 1705-1712;

Main menu

User menu

Search

Most cited article(s)

Pages

Navigate

More Information

ASPET's Other Journals